Details of the Drug Reposition

General Information of This Drug (ID: DMHZCPO)

Drug Name
Ibrutinib   DMHZCPO
Synonyms PCI-32765; Ibrutinib (BTK inhibitor)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Mantle cell lymphoma DISFREOV 2A85.5 Approved [1]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Approved [2]
Small lymphocytic lymphoma DIS30POX 2A82.0 Approved [3]
------------------------------------------------------------------------------------
4 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Follicular lymphoma DISVEUR6 2A80 Phase 3 [4]
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 3 [4]
Non-hodgkin lymphoma DISS2Y8A 2B33.5 Phase 3 [4]
Pancreatic cancer DISJC981 2C10 Phase 3 [4]
------------------------------------------------------------------------------------
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [4]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6912).
2 Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
3 Ibrutinib FDA Label
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)